Publication | Closed Access
Overview of Short-Term and Long-Term Safety of Brexpiprazole in Patients with Major Depressive Disorder and Inadequate Response to Antidepressant Treatment
20
Citations
0
References
2016
Year
Psychotropic MedicationPsychopharmacologyAdjunctive TreatmentPharmacotherapyLong-term SafetySocial SciencesInadequate ResponsePsychiatryDepressionSerotonin-dopamine Activity ModulatorClinical PsychiatryPsychiatric DisorderPharmacologySide EffectSchizophreniaMajor Depressive DisorderMood DisordersBiological PsychiatryDrug TherapyMedicinePsychopathology
Background: Many patients with major depressive disorder (MDD) do not respond adequately to first-line antidepressant treatment (ADT). Adjunctive treatment with second-generation antipsychotics has demonstrated efficacy for patients with MDD, but is limited by tolerability and safety issues. The recently introduced serotonin-dopamine activity modulator, brexpiprazole, has demonstrated efficacy as an adjunctive treatment for MDD. Keywords: Adjunctive therapy, antipsychotics, brexpiprazole, major depressive disorder, safety, clinical trials.